As surgical techniques continue to develop, for example as seen with the Norwood procedure for hypoplastic left heart syndrome, the number of patients with the most complex forms of CHD will continue to increase along with their associated long term complications. Our ability to manage these patients appropriately, therefore, must also develop alongside. The purpose of this review is to examine the management of these patients once they have developed advanced disease, including drug therapy, devices, transplant and end of life care. In particular, the unique problems posed by patients with a systemic right ventricle (RV) and univentricular circulations are discussed.
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Drug therapy is often first line in the management of these patients, with experience gained from acquired heart failure often being applied. However, patients with congenital heart disease were excluded from all the major chronic heart failure studies and, due to their unique anatomical and physiological abnormalities, should be considered a very different population. To date, though, most trials in this population involve small patient numbers and frequently use surrogate end points. (12) Two groups of patients who pose specific problems in the management of ventricular failure are those with a systemic right ventricle (RV) and a univentricular circulation.
The RV does not behave like a normal left ventricle (LV) when in the subaortic position, either in congenitally corrected transposition of the great arteries (cTGA) or transposition of the great arteries (TGA) with a previous atrial switch. As a result systemic RV dysfunction is common in these adult patients with the prevalence increasing with age. (13) (14) (15) (16) Whilst the number of patients with a previous atrial switch is decreasing due to the introduction of the arterial switch operation in the 1980s, (12) the current population is ageing and will therefore be at a higher risk of developing long term sequelae of their condition, including ventricular dysfunction, atrial arrhythmias and death.
The systemic RV is known to have extensive myocardial fibrosis and hypertrophy and these correlate well with the degree of ventricular dysfunction. (17) (18) (19) Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have previously been shown to decrease myocardial fibrosis and attenuate ventricular remodelling with a resultant increase in myocardial function and decrease in mortality in patients with both asymptomatic and symptomatic left ventricular dysfunction. (20) (21) (22) (23) There have been several small trials using ACEIs and ARBs in patients with a systemic RV but results have been disappointing. (17, 24, 25) A recent placebo-controlled study from the Netherlands studied the effect of the ARB valsartan on patients with either a previous atrial repair for TGA or cTGA. (26) Eighty eight patients were enrolled, 44
receiving valsartan and 44 placebo with a follow up of three years.
The authors found no difference in MRI-derived RVEF, quality of life or exercise capacity between the valsartan and placebo group.
Similarly, beta blockers are known to improve LV function, reverse remodelling and reduce morbidity and mortality in patients with chronic LV dysfunction. (27, 28) A recent preliminary study looked at the effect of eplerenone, a selective aldosterone antagonist, on patients with a systemic RV.
They showed that whilst it was associated with reduced levels of collagen turnover biomarkers, suggesting a reduction in myocardial fibrosis, there were no changes in MRI derived parameters of ventricular function.
Clinical heart failure in patients with a previous Fontan operation is increasingly common with age occurring in up to 40% of patients 16 years after repair. (14) (40) Whilst they failed to show an increase in peak oxygen consumption, they did find a significant improvement in ventilator efficiency during peak and submaximal exercise.
A further study gave sildenafil to a similar population and after just one week demonstrated and increase in ventricular systolic elastance and improved ventriculo-arterial coupling.
(43)
IMPLANTABLE CARDIAC DEFIBRILLATORS (ICDs)
Arrhythmias are common in adult congenital heart disease (ACHD) patients and are an important determinant in the morbidity and mortality of this population (3, (8) (9) (10) 44) with the risk of late sudden cardiac death (SCD) being 25-100 times greater than that of an aged matched control population, (45) the risk increasing after the second decade following surgery. Arrhythmias may be intrinsic to the underlying abnormality, such as an accessory pathway in Ebstein's anomaly, or due to long term sequelae from its palliation, such as extensive suture lines, chronic haemodynamic disturbances or long term cyanosis. (46, 47) The risk of arrhythmias and SCD appears to be highest in those with surgically repaired
Tetralogy of Fallots (TOF), (48) and TGA with an atrial switch. (45, 49, 50) Czosek, et al. studied 589 Holter monitors in 189 patients with CHD. (51) They found that non-sustained ventricular tachycardia (NSVT) was associated with SCD in patients with TOF but not in those with previous atrial switches or Fontan operation. They concluded that Holter monitors overall have a low positive predictive value for clinically significant arrhythmias but a high negative predictive value. Other high risk features of SCD identified in patients with TOF include a QRS duration >180ms on a resting ECG, (52) a lengthening QRS late after surgery (53) 
CARDIAC RESYNCHRONISATION THERAPY (CRT)
The use of cardiac resynchronisation therapy in heart failure secondary to ischaemic and dilated cardiomyopathies is now well established with clear indications and guidelines. (66, 67) Its role in congenital heart disease, however, is less well defined and it may not be appropriate to extrapolate the findings of the large trials performed in acquired heart failure to this population. (68, 69) ACHD patients are a heterogeneous population and frequently have different forms of dyssynchrony, including a predominance of RBBB. Thus, for systemic right ventricles, it may be that CRT implantation should be considered as an adjunct to right AV valve intervention. (69, 70) 
CARDIAC TRANSPLANTATION IN ACHD
As increasing numbers of patients born with complex congenital heart disease reach adulthood, there will be an inevitable rise in the number of patients who develop advanced disease in whom conventional medical and surgical therapy has failed, with an estimated 10-20% of all patients with complex ACHD eventually demonstrating the need for a transplant. (73) In many of these patients, heart or heart and lung transplantation is the only definitive treatment to improve survival and quality of life. (74) Transplantation in patients with ACHD, however, has previously been perceived to be associated with poor outcome, when compared to other indications (75, 76) with Taylor, et al. stating "the diagnosis of ACHD is a powerful risk factor for death at one year after transplant". (77) Problems specific to this population include complex anatomy often with multiple previous operations (74, 76, 78) and an elevated pulmonary vascular resistance (PVR), a known risk factor for early donor organ failure. (79) Further to these, HLA sensitisation is common, especially in those patients who have undergone previous surgery with a homograft. (80) HLA sensitisation, as indicated by elevated panel reactive antibodies (PRA), is associated with a worse outcome following transplant, especially for those with a PRA >25%, as well as decreased chances of getting a successful organ match. (81) Despite these problems, the numbers of patients with CHD being referred for transplantation has increased over the past 15 years. (74, 78) However, the overall proportion of transplants for underlying CHD remains small and account for just 2% of all transplants performed. (82) Thus, many studies are small, single centre studies.
Irving, et al. looked at all adults with CHD who underwent transplantation in a single UK centre. (76) They report on 37 patients, 41% of whom had a univentricular circulation and 22% had TGA with a previous Mustard or Senning repair. They found a 30 day survival of 70.3% which was higher than patients with other indications; however their long term survival was comparable. Two larger studies from the US examined all transplants recorded in a nationwide registry and database. (74, 78) However, unlike Irving, et al., the type of CHD was not recorded. Davies, et al. identified 1 035 adult patients with CHD who were listed for primary cardiac transplantation (2.5% of the total number). (78) They found that patients with CHD were on the waiting list for a longer time and, again demonstrated a higher early mortality in those with CHD (18.9% vs 9.6%) but an equivalent 10 year mortality (52.8% vs 53.6%). Similar results were also found by Patel, et al. who further reported that patients with CHD who underwent transplantation had significantly longer intraoperative ischaemic times. (74) Furthermore they noted that the underlying causes for the excess early mortality included complex anatomy, right ventricular failure due to elevated PVR and a more debilitated condition prior to surgery.
Patients with a univentricular circulation account for the greatest number of CHD referrals for cardiac transplantation from the age of six months to adulthood. (83) 
VENTRICULAR ASSIST DEVICES
The use of ventricular assist devices (VADs) is becoming increasingly widespread in patients with acquired heart failure (86) as either a bridge to transplant or recovery. (79, (87) (88) (89) Whilst their use in ACHD is increasing, their success is mainly reported in a number of case reports with no large randomised trial available to date.
Furthermore, patients with CHD listed for cardiac transplantation are less likely to have mechanical support, including a VAD, than those with acquired heart failure. (78, 90) As discussed above, univentricular hearts account for the greatest number of CHD referrals for transplant. Thus, there has been much interest in the benefit of VADs in this growing population.
A number of case reports have shown that VADs in patients with a Fontan circulation can facilitate the recovery of circulatory, metabolic and pulmonary abnormalities. (91, 92) They can be beneficial if the underlying problem is ventricular dysfunction (93) or normal ventricular function but high venous pressures. (94) However, previous studies have shown that showed that in children with univentricular circulations, the use of the Berlin heart VAD was associated with only a 50% chance of survival to transplantation compared to an overall survival of 70-86% in all children with a VAD. (95) (96) (97) New devices that specifically increase ADVANCED ACHD
Spring 2013
Volume 10 • Number 4 the blood flow through the systemic venous return through the lungs are being designed, for example a pump in the IVC and hepatic blood flow to give mechanical cavopulmonary assistance. (98) Similarly, case reports have reported some success with the use of VADs in patients with systemic right ventricles. (99, 100) Joyce, et al.
however report complications arising from the positioning of the cannulae due anatomical differences in the right ventricle.
END OF LIFE CARE
The role of early and proactive discussion regarding end of life (EOL) care is of proven benefit in oncology and acquired heart failure (101) (102) (103) and leads to less aggressive medical care at the end of life and earlier referral for hospice care. However, a recent study by Tobler, et al. reported that in a survey of adults with CHD, only 1% of patients had discussed EOL planning, whereas 50% of their physicians reported regularly discussing these issues. (104) Furthermore they found that 78% of these patients wished to discuss EOL issues, 62% wishing for this to be done at an early stage and this was irrespective of disease severity. A further study by this group looked at the experience of adults with CHD who died in hospital and found that only 10% had documented EOL discussions with active resuscitation less likely to happen in these patients.
As cardiologists we frequently extrapolate our experience from that gained in acquired heart failure including in EOL care. However, patients with CHD have important differences. Firstly they have a lifelong illness and there is often no triggering event for the deterioration, making timing of discussion difficult to judge in many cases. (106) Furthermore, these patients are young with the median age of patients with severe CHD being just 29 years. (4) With increasing survivors of the Norwood operation now reaching adulthood, the number of young adults is likely to increase.
Oncologists have identified that young patients have unique needs, often needing a more collaborative approach with their physician with regards to their care planning. (107) A previous study in young patients with cancer showed that EOL discussions often don't occur until very close to death, with barriers to communication including a desire to protect and difficulties dealing with personal emotions. (108) There is frequently a difficult balance between life-prolonging interventions, such as transplantation, and end of life care. Ideally patients should have a parallel approach to their care with a study looking at patients with acquired heart failure being assessed for
VADs showing that this approach leads to clearer post-operative care and more effective management of complications. (109) As the number of patients with advanced disease continues to increase, we must acknowledge that this is an important, and currently often lacking, part of our patients' on-going care. EOL discussion and planning should become a routine part of their assessment and their unique needs and preferences addressed. Conflict of interest: none declared.
